



# PROVIDER BULLETIN

<b>Aetna Better Health® of Florida</b> 9675 NW 117 <sup>th</sup> Ave, Suite 202 Miami, FL 33178  <b>AetnaBetterHealth.com/Florida</b>	<b>Date:</b>	June 25, 2024
	<b>Purpose:</b>	Formulary Change: Hadlima has been added to Medicaid preferred drug list
	<b>Subject:</b>	Hadlima added to Medicaid PDL
	<b>Products:</b>	Medicaid (MMA)
	<b>From:</b>	Pharmacy

## Aetna Better Health® of Florida

### Hadlima has been added to Medicaid (MMA) preferred drug list

Dear Providers,

Hadlima has recently been added to the Medicaid (MMA) preferred drug list. Hadlima (adalimumab-bwvd) is a biosimilar and is now available at parity to Humira. Hadlima is 85% less expensive than Humira and has no clinically meaningful differences in safety, purity, and potency compared with Humira.

Like Humira, Hadlima is indicated for the treatment of Rheumatic Arthritis, Chron's Disease, Plaque Psoriasis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Hidradenitis Suppurativa, and Uveitis.

Hadlima is available as a push touch auto-injector as well as prefilled syringes in both 40 mg/0.8ml and 40 mg/0.4ml concentrations. Hadlima can be dosed at a 1:1 conversion ratio with Humira since dosing for approved indications is the same.

Please consider Hadlima when prescribing. **Since Hadlima is not automatically interchangeable, a new script for Hadlima must be sent to the pharmacy for new starts or to switch members from Humira.**

Thank you for your continued participation in the Aetna Better Health of Florida network. Please contact our Provider Services line should you have any questions at:

**Phone:** MMA: **1-800-441-5501**

LTC: **1-844-645-7371**

FHK: **1-844-528-5815**

**Email:** [FLProviderEngagement@aetna.com](mailto:FLProviderEngagement@aetna.com)

Thank you,

**Aetna Better Health of Florida**

CONFIDENTIALITY NOTICE: This message is intended only for the user of the individual or entity to which it is addressed and may contain confidential and proprietary information. If you are not the intended recipient of the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is prohibited. If you received this communication in error, please notify the sender at the phone number above. **NOTICE TO RECIPIENT(S) OF INFORMATION:** Information disclosed to you pertaining to alcohol or drug abuse treatment is protected by federal confidentiality rules (42 CFR Part 2), which prohibit any further disclosure of this information by you without express written consent of the person to whom it pertains or as otherwise permitted by 42 CFR Part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. The federal rules restrict any use of the information to criminally investigate or prosecute any alcohol or drug abuse patient.

*For providers only, not intended for members distribution and or marketing material.*

**AetnaBetterHealth.com/Florida**

FL-24-06-05